Astellas Pharma to acquire avacincaptad pegol developer Iveric Bio for $6bn

Japanese pharma company Astellas Pharma has agreed to acquire Nasdaq-listed Iveric Bio in an all-cash deal worth around $5.9 billion with an aim to create ... Read More